Patents by Inventor Derrick Ryan Witcher

Derrick Ryan Witcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20230159630
    Abstract: Provided herein are methods and uses of antibodies that bind all seven human ELR+CXC chemokines with high affinity for preventing and/or treating respiratory diseases, e.g., acute respiratory distress syndrome (ARDS). The present invention also relates to doses and dosing regimens for the methods and uses of antibodies that bind all seven human ELR+CXC chemokines with high affinity for preventing and/or treating respiratory diseases, e.g., ARDS.
    Type: Application
    Filed: April 16, 2021
    Publication date: May 25, 2023
    Inventors: Dipak R Patel, Derrick Ryan Witcher, Michael Edward Woodman
  • CD200 RECEPTOR ANTAGONIST BINDING MOLECULES
    Publication number: 20220396619
    Abstract: The present invention relates to antagonist polypeptide molecules that bind to human CD200 receptor, and are useful for treating solid tumors, alone and in combination with chemotherapy, ionizing radiation, an antitumor agent and/or an immuno-oncology agent.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 15, 2022
    Inventors: Katherine Marie BELL-MCGUINN, Stephen John DEMAREST, Kyla Elizabeth DRISCOLL, Rikke Baek HOLMGAARD, Anna Marie RUSSELL, Jaafar Nassar SLEIMAN HAIDAR, Derrick Ryan WITCHER
  • CD200R AGONIST ANTIBODIES AND USES THEREOF
    Publication number: 20220251198
    Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
    Type: Application
    Filed: April 21, 2022
    Publication date: August 11, 2022
    Inventors: Stephen J. Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
  • CD200R agonist antibodies and uses thereof
    Patent number: 11319370
    Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: May 3, 2022
    Assignee: Eli Lilly and Company
    Inventors: Stephen J Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
  • PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA
    Publication number: 20210340244
    Abstract: Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.
    Type: Application
    Filed: October 15, 2019
    Publication date: November 4, 2021
    Inventors: Kristine Kay Kikly, Dipak Ratilal Patel, Derrick Ryan Witcher
  • Pan-ELR+ CXC chemokine antibodies
    Patent number: 10858425
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: December 8, 2020
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • CD200R AGONIST ANTIBODIES AND USES THEREOF
    Publication number: 20200087395
    Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 19, 2020
    Inventors: Stephen J Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20180362631
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 20, 2018
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR+ CXC chemokine antibodies
    Patent number: 10093727
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher, Sudhakar Reddy Chintharlapalli
  • Anti-CD20? / anti-BAFF bispecific antibodies
    Patent number: 9951146
    Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: April 24, 2018
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Kristine Kay Kikly, Derrick Ryan Witcher
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20170362315
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 21, 2017
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR CXC chemokine antibodies
    Patent number: 9783605
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: October 10, 2017
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Derrick Ryan Witcher, Beth Ann Strifler
  • ANTI-CD20- / ANTI-BAFF BISPECIFIC ANTIBODIES
    Publication number: 20160289342
    Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.
    Type: Application
    Filed: March 24, 2016
    Publication date: October 6, 2016
    Inventors: Barrett Allan, Kristine Kay Kikly, Derrick Ryan Witcher
  • Anti-TNF-anti-IL-17 bispecific antibodies
    Patent number: 9416182
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: August 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • PAN-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20160152699
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: February 3, 2016
    Publication date: June 2, 2016
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Derrick Ryan Witcher, Beth Ann Strifler
  • Pan-ELR+ CXC Chemokine Antibodies
    Patent number: 9290570
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: March 22, 2016
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20140271647
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES
    Publication number: 20140255406
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Anti-hepcidin antibodies and uses thereof
    Patent number: 8765129
    Abstract: Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: July 1, 2014
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Barbara Anne Swanson, Ying Tang, Derrick Ryan Witcher
  • Anti-ferroportin 1 monoclonal antibodies and uses thereof
    Patent number: 8679497
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: March 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Joseph Vincent Manetta, Ying Tang, Derrick Ryan Witcher